Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1147461.RA8DA52VywDraASJC2q22hxItZdAOOvPPuCz0EK6i2IgE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1147461.RA8DA52VywDraASJC2q22hxItZdAOOvPPuCz0EK6i2IgE130_assertion type Assertion NP1147461.RA8DA52VywDraASJC2q22hxItZdAOOvPPuCz0EK6i2IgE130_head.
- NP1147461.RA8DA52VywDraASJC2q22hxItZdAOOvPPuCz0EK6i2IgE130_assertion wasGeneratedBy ECO_0000203 NP1147461.RA8DA52VywDraASJC2q22hxItZdAOOvPPuCz0EK6i2IgE130_provenance.
- NP1147461.RA8DA52VywDraASJC2q22hxItZdAOOvPPuCz0EK6i2IgE130_assertion wasDerivedFrom befree-2016 NP1147461.RA8DA52VywDraASJC2q22hxItZdAOOvPPuCz0EK6i2IgE130_provenance.
- NP1147461.RA8DA52VywDraASJC2q22hxItZdAOOvPPuCz0EK6i2IgE130_assertion SIO_000772 24451154 NP1147461.RA8DA52VywDraASJC2q22hxItZdAOOvPPuCz0EK6i2IgE130_provenance.
- NP1147461.RA8DA52VywDraASJC2q22hxItZdAOOvPPuCz0EK6i2IgE130_assertion evidence source_evidence_literature NP1147461.RA8DA52VywDraASJC2q22hxItZdAOOvPPuCz0EK6i2IgE130_provenance.
- NP1147461.RA8DA52VywDraASJC2q22hxItZdAOOvPPuCz0EK6i2IgE130_assertion description "[Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1147461.RA8DA52VywDraASJC2q22hxItZdAOOvPPuCz0EK6i2IgE130_provenance.